{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:34:12Z","timestamp":1775680452956,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T00:00:00Z","timestamp":1579046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jiangsu Provincial Key Project","award":["BE2018657"],"award-info":[{"award-number":["BE2018657"]}]},{"name":"the Jiangsu Medical Innovation Team","award":["No. CXDT-37"],"award-info":[{"award-number":["No. CXDT-37"]}]},{"name":"Suzhou Introduced Project of Clinical Medical Expert Team","award":["SZYJTD201804"],"award-info":[{"award-number":["SZYJTD201804"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>The benefit of adjuvant radiotherapy (ART) for extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBC) is unclear, with conflicting results from nonrandomized studies. We reported a meta-analysis to determine the impact of adjuvant radiotherapy on survival.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>PubMed, EMBASE, Cochrane Library and CNKI databases were searched to identify clinical trials of postoperative ART versus no radiotherapy for EHCC and GBC. The obtained data were analyzed using RevMan 5.3 and Stata 14.0 statistical software. Differences between two groups were estimated by calculating the odds ratio (OR) and 95% confidence interval (CI).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 21 clinical trials involving 1465 EHCC and GBC patients were selected according to the inclusion and exclusion criteria and included in this meta-analysis. The meta-analysis showed the following: The 5-year overall survival (OS) rate was higher in the ART group than in the no radiotherapy group (OR\u2009=\u20090.63; 95% CI\u2009=\u20090.50\u20130.81, <jats:italic>p<\/jats:italic>\u2009=\u20090.0002). The 5-year OS rate was significantly higher for those with lymph node-positive disease (OR\u2009=\u20090.15; 95% CI 0.07\u20130.35; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001) and margin-positive disease (OR\u2009=\u20090.40; 95% CI 0.19\u20130.85; <jats:italic>p<\/jats:italic>\u2009=\u20090.02) in the ART group than in the no radiotherapy group. ART had a tendency to bring benefit to the 5-year OS of patients with margin-negative disease but the difference was not statistically significant (OR\u2009=\u20090.57, 95% CI 0.30\u20131,07, <jats:italic>p<\/jats:italic>\u2009=\u20090.08). The local recurrence rate was significantly lower in the ART group than in the no radiotherapy group (OR\u2009=\u20090.54; 95% CI\u2009=\u20090.38\u20130.76, <jats:italic>p<\/jats:italic>\u2009=\u20090.0004), and there was no significant difference in the distant metastasis rate between the two groups (OR\u2009=\u20091.33; 95% CI\u2009=\u20090.95\u20131.87, <jats:italic>p<\/jats:italic>\u2009=\u20090.10).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>A meta-analysis of the existing study results showed that compared with no radiotherapy, ART is an effective postoperative treatment for EHCC and GBC.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13014-020-1459-x","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T17:05:05Z","timestamp":1579107905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma"],"prefix":"10.1186","volume":"15","author":[{"given":"Bixin","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,15]]},"reference":[{"issue":"1","key":"1459_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"CA Cancer J Clin"},{"issue":"24","key":"1459_CR2","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","volume":"33","author":"E Ben-Josef","year":"2015","unstructured":"Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant Capecitabine and gemcitabine followed by radiotherapy and concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33(24):2617\u201322. https:\/\/doi.org\/10.1200\/JCO.2014.60.2219.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1459_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11894-017-0542-4","volume":"19","author":"B Doherty","year":"2017","unstructured":"Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of Cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19(1):2. https:\/\/doi.org\/10.1007\/s11894-017-0542-4.","journal-title":"Curr Gastroenterol Rep"},{"issue":"9935","key":"1459_CR4","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","volume":"383","author":"N Razumilava","year":"2014","unstructured":"Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(13)61903-0.","journal-title":"Lancet"},{"issue":"24","key":"1459_CR5","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1002\/cncr.30254","volume":"122","author":"M Javle","year":"2016","unstructured":"Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, et al. Biliary Cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838\u201347. https:\/\/doi.org\/10.1002\/cncr.30254.","journal-title":"Cancer"},{"key":"1459_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mrrev.2018.08.003","volume":"778","author":"R Mehrotra","year":"2018","unstructured":"Mehrotra R, Tulsyan S, Hussain S, Mittal B, Singh Saluja S, Singh S, et al. Genetic landscape of gallbladder cancer: global overview. Mutat Res. 2018;778:61\u201371. https:\/\/doi.org\/10.1016\/j.mrrev.2018.08.003.","journal-title":"Mutat Res"},{"issue":"8","key":"1459_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","volume":"15","author":"D Malka","year":"2014","unstructured":"Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardi\u00e8re C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014;15(8):819\u201328. https:\/\/doi.org\/10.1016\/S1470-2045(14)70212-8.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1459_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/SLA.0000000000000827","volume":"262","author":"Y Takahashi","year":"2015","unstructured":"Takahashi Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Surgery for recurrent biliary tract Cancer: a single-center experience with 74 consecutive resections. Ann Surg. 2015;262(1):121\u20139. https:\/\/doi.org\/10.1097\/SLA.0000000000000827.","journal-title":"Ann Surg"},{"key":"1459_CR9","doi-asserted-by":"publisher","first-page":"7375169","DOI":"10.1155\/2018\/7375169","volume":"2018","author":"G Hu","year":"2018","unstructured":"Hu G, Liu Q, Ma JY, Liu CY. Prognostic significance of platelet-to-lymphocyte ratio in Cholangiocarcinoma: a meta-analysis. Biomed Res Int. 2018;2018:7375169. https:\/\/doi.org\/10.1155\/2018\/7375169.","journal-title":"Biomed Res Int"},{"issue":"4","key":"1459_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semradonc.2018.06.004","volume":"28","author":"PJ Boimel","year":"2018","unstructured":"Boimel PJ, Binder KR, Hong TS, Feng M, Ben-Josef E. Cholangiocarcinoma and gallbladder cases: an expert panel case-based discussion. Semin Radiat Oncol. 2018;28(4):351\u201361. https:\/\/doi.org\/10.1016\/j.semradonc.2018.06.004.","journal-title":"Semin Radiat Oncol"},{"issue":"13","key":"1459_CR11","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1245\/s10434-017-6095-9","volume":"24","author":"BL Ecker","year":"2017","unstructured":"Ecker BL, Vining CC, Roses RE, Maggino L, Lee MK, Drebin JA, et al. Identification of patients for adjuvant therapy after resection of carcinoma of the Extrahepatic bile ducts: a propensity score-matched analysis. Ann Surg Oncol. 2017;24(13):3926\u201333. https:\/\/doi.org\/10.1245\/s10434-017-6095-9.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1459_CR12","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ijrobp.2008.09.017","volume":"74","author":"ET Shinohara","year":"2009","unstructured":"Shinohara ET, Mitra N, Guo M, Metz JM. Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;74(4):1191\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.09.017.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1459_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijrobp.2010.05.001","volume":"81","author":"ET Shinohara","year":"2011","unstructured":"Shinohara ET, Mitra N, Guo M, Metz JM. Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2011;81(1):189\u201398. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.05.001.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1459_CR14","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.gassur.2005.12.002","volume":"10","author":"P Balachandran","year":"2006","unstructured":"Balachandran P, Agarwal S, Krishnani N, Pandey CM, Kumar A, Sikora SS, et al. Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg. 2006;10(6):848\u201354. https:\/\/doi.org\/10.1016\/j.gassur.2005.12.002.","journal-title":"J Gastrointest Surg"},{"issue":"11","key":"1459_CR15","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1245\/s10434-008-9998-7","volume":"15","author":"Y Borghero","year":"2008","unstructured":"Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant Chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008;15(11):3147\u201356. https:\/\/doi.org\/10.1245\/s10434-008-9998-7.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"1459_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ejso.2006.09.033","volume":"33","author":"Q Cheng","year":"2007","unstructured":"Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Predictive factors for prognosis of hilar cholangiocarcinoma: Postresection radiotherapy improves survival. Eur J Surg Oncol. 2007;33(2):202\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2006.09.033.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"1459_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00268-002-6434-1","volume":"27","author":"MF Gerhards","year":"2003","unstructured":"Gerhards MF, van Gulik TM, Gonz\u00e1lez Gonz\u00e1lez D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for Resectable Hilar Cholangiocarcinoma. World J Surg. 2003;27(2):173\u20139. https:\/\/doi.org\/10.1007\/s00268-002-6434-1.","journal-title":"World J Surg"},{"issue":"1","key":"1459_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijrobp.2008.10.052","volume":"75","author":"DG Gold","year":"2009","unstructured":"Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, et al. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2009;75(1):150\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.052.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1459_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijrobp.2017.09.029","volume":"100","author":"B Gu","year":"2018","unstructured":"Gu B, Qian L, Yu H, Hu J, Wang Q, Shan J, et al. Concurrent Chemoradiotherapy in curatively resected gallbladder carcinoma: a propensity score-matched analysis. Int J Radiat Oncol Biol Phys. 2018;100(1):138\u201345. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.09.029.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1459_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/01.COC.0000026833.73428.1F","volume":"26","author":"DE Heron","year":"2003","unstructured":"Heron DE, Stein DE, Eschelman DJ, Topham AK, Waterman FM, Rosato EL, et al. Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol. 2003;26(4):422\u20138. https:\/\/doi.org\/10.1097\/01.COC.0000026833.73428.1F.","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"1459_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ijrobp.2006.11.048","volume":"68","author":"MA Hughes","year":"2007","unstructured":"Hughes MA, Frassica DA, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, et al. Adjuvant concurrent chemoradation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007;68(1):178\u20132. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.11.048.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1459_CR22","doi-asserted-by":"publisher","first-page":"583","DOI":"10.4143\/crt.2015.091","volume":"48","author":"JH Im","year":"2016","unstructured":"Im JH, Seong J, Lee IJ, Park JS, Yoon DS, Kim KS, et al. Surgery alone versus surgery followed by chemotherapy and radiotherapy in resected Extrahepatic bile duct Cancer: treatment outcome analysis of 336 patients. Cancer Res Treat. 2016;48(2):583\u201395. https:\/\/doi.org\/10.4143\/crt.2015.091.","journal-title":"Cancer Res Treat"},{"issue":"12","key":"1459_CR23","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s10620-005-3040-8","volume":"50","author":"H Itoh","year":"2005","unstructured":"Itoh H, Nishijima K, Kurosaka Y, Takegawa S, Kiriyama M, Dohba S, et al. Magnitude of combination therapy of radical resection and external beam radiotherapy for patients with carcinomas of the extrahepatic bile duct and gallbladder. Dig Dis Sci. 2005;50(12):2231\u201342. https:\/\/doi.org\/10.1007\/s10620-005-3040-8.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1459_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s11605-009-1140-z","volume":"14","author":"WS Kim","year":"2010","unstructured":"Kim WS, Choi DW, You DD, Ho CY, Heo JS, Choi SH. Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg. 2010;14(4):679\u201387. https:\/\/doi.org\/10.1007\/s11605-009-1140-z.","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"1459_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3760\/cma.j.im.1007-631X.2012.06.003","volume":"27","author":"JW Liang","year":"2012","unstructured":"Liang JW, Wang Z, Zhou ZX, et al. Value of postoperative adjuvant therapy for gallbladder carcinoma. Chin J Gen Surg. 2012;27(6):445\u20138. https:\/\/doi.org\/10.3760\/cma.j.im.1007-631X.2012.06.003.","journal-title":"Chin J Gen Surg"},{"issue":"4","key":"1459_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.4174\/jkss.2012.83.4.227","volume":"83","author":"HY Lee","year":"2012","unstructured":"Lee HY, Kim YH, Jung GJ, Roh YH, Park SY, Kang NU, et al. Prognostic factors for gallbladder cancer in the laparoscopy era. J Korean Surg Soc. 2012;83(4):227\u201336. https:\/\/doi.org\/10.4174\/jkss.2012.83.4.227.","journal-title":"J Korean Surg Soc"},{"issue":"50","key":"1459_CR27","first-page":"310","volume":"50","author":"G Lindell","year":"2003","unstructured":"Lindell G, Holmin T, Ewers SB, Tranberg KG, Stenram U, Ihse I. Extended operation with or without intraoperative (IORT) and external (EBRT) radiotherapy for gallbladder carcinoma. Hepatogastroenterology. 2003;50(50):310\u20134.","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"1459_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3760\/j.issn:1004-4221.2006.02.010","volume":"15","author":"Y Meng","year":"2006","unstructured":"Meng Y, Xiao ZP, Zhang BH. The value of radiotherapy after radical resection of locally advanced hilar cholangiocarcinoma. Chin J Radiat Oncol. 2006;15(2):114\u20136. https:\/\/doi.org\/10.3760\/j.issn:1004-4221.2006.02.010.","journal-title":"Chin J Radiat Oncol"},{"issue":"6","key":"1459_CR29","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1097\/00000658-199506000-00017","volume":"221","author":"HA Pitt","year":"1995","unstructured":"Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, et al. Perihilar cholangiocarcinoma: postoperative radiotherapy does not improve survival. Ann Surg. 1995;221(6):788\u201397.","journal-title":"Ann Surg"},{"issue":"7","key":"1459_CR30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00595-005-2989-4","volume":"35","author":"N Sagawa","year":"2005","unstructured":"Sagawa N, Kondo S, Morikawa T, Okushiba S, Katoh H. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today. 2005;35(7):548\u201352. https:\/\/doi.org\/10.1007\/s00595-005-2989-4.","journal-title":"Surg Today"},{"issue":"27","key":"1459_CR31","first-page":"1585","volume":"46","author":"T Todoroki","year":"1999","unstructured":"Todoroki T, Kawamoto T, Otsuka M, Koike N, Yoshida S, Takada Y, et al. Benefits of combining radiotherapy with aggressive resection for stage IV gallbladder cancer. Hepatogastroenterology. 1999;46(27):1585\u201391.","journal-title":"Hepatogastroenterology"},{"issue":"3","key":"1459_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0360-3016(99)00472-1","volume":"46","author":"T Todoroki","year":"2000","unstructured":"Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys. 2000;46(3):581\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"S3","key":"1459_CR33","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1245\/s10434-015-4685-y","volume":"22","author":"J Wang","year":"2015","unstructured":"Wang J, Narang AK, Sugar EA, Luber B, Rosati LM, Hsu CC, et al. Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience. Ann Surg Oncol. 2015;22(S3):1100\u20136. https:\/\/doi.org\/10.1245\/s10434-015-4685-y.","journal-title":"Ann Surg Oncol"},{"key":"1459_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/(SICI)1520-6823(1998)6:5<240::AID-ROI6>3.0.CO;2-R","volume":"6","author":"RA Zlotecki","year":"1998","unstructured":"Zlotecki RA, Jung LA, Vauthey JN, Vogel SB, Mendenhall WM. Carcinoma of the extrahepatic biliary tract: surgery and radiotherapy for curative and palliative intent. Radiat Oncol Investig. 1998;6:240\u20137. https:\/\/doi.org\/10.1002\/(SICI)1520-6823(1998)6:5<240::AID-ROI6>3.0.CO;2-R.","journal-title":"Radiat Oncol Investig"},{"issue":"16","key":"1459_CR35","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","volume":"30","author":"AM Horgan","year":"2012","unstructured":"Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract Cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934\u201340. https:\/\/doi.org\/10.1200\/JCO.2011.40.5381.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1459_CR36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ctrv.2011.05.003","volume":"38","author":"M Bonet Beltr\u00e1n","year":"2012","unstructured":"Bonet Beltr\u00e1n M, Allal AS, Gich I, Sol\u00e9 JM, Carri\u00f3 I. Is adjuvant radiotherapy needed after curative resection of extrahepatic biliary tract cancers? A systematic review with a meta-analysis of observational studies. Cancer Treat Rev. 2012;38(2):111\u20139. https:\/\/doi.org\/10.1016\/j.ctrv.2011.05.003.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"1459_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1245\/s10434-017-6139-1","volume":"25","author":"BH Kim","year":"2018","unstructured":"Kim BH, Kwon J, Chie EK, Kim K, Kim YH, Seo DW, et al. Adjuvant Chemoradiotherapy is associated with improved survival for patients with resected gallbladder carcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25(1):255\u201364. https:\/\/doi.org\/10.1245\/s10434-017-6139-1.","journal-title":"Ann Surg Oncol"},{"key":"1459_CR38","volume-title":"Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers, Version 1","author":"National Comprehensive Cancer Network (NCCN)","year":"2019","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers, Version 1. 2019. https:\/\/www.nccn.org\/patients\/guidelines\/hepatobiliary\/index.html."},{"issue":"suppl 5","key":"1459_CR39","doi-asserted-by":"publisher","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","volume":"27","author":"JW Valle","year":"2016","unstructured":"Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28\u201337. https:\/\/doi.org\/10.1093\/annonc\/mdw324.","journal-title":"Ann Oncol"},{"issue":"12","key":"1459_CR40","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.18.02178","volume":"37","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract Cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015\u201327. https:\/\/doi.org\/10.1200\/JCO.18.02178.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1459_CR41","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jhbp.233","volume":"22","author":"M Miyazaki","year":"2015","unstructured":"Miyazaki M, Yoshitomi H, Miyakawa S, Uesaka K, Unno M, Endo I, et al. Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci. 2015;22(4):249\u201373. https:\/\/doi.org\/10.1002\/jhbp.233.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"12","key":"1459_CR42","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s12094-015-1436-2","volume":"17","author":"M Benavides","year":"2015","unstructured":"Benavides M, Ant\u00f3n A, Gallego J, G\u00f3mez MA, Jim\u00e9nez-Gordo A, La Casta A, et al. Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol. 2015;17(12):982\u20137. https:\/\/doi.org\/10.1007\/s12094-015-1436-2.","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"1459_CR43","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.bpg.2016.08.003","volume":"30","author":"TB Brunner","year":"2016","unstructured":"Brunner TB, Seufferlein T. Radiation therapy in cholangiocellular carcinomas. Best Pract Res Clin Gastroenterol. 2016;30(4):593\u2013602. https:\/\/doi.org\/10.1016\/j.bpg.2016.08.003.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"5","key":"1459_CR44","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30915-X.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1459_CR45","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.18.00050","volume":"37","author":"J Edeline","year":"2019","unstructured":"Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and Oxaliplatin chemotherapy or surveillance in resected biliary tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;37(8):658\u201367. https:\/\/doi.org\/10.1200\/JCO.18.00050.","journal-title":"J Clin Oncol"},{"key":"1459_CR46","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","volume":"15","author":"A Stein","year":"2015","unstructured":"Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Kl\u00fcmpen HJ, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)-a randomized, multidisciplinary, multinational phase III trial. BMC Cancer. 2015;15:564. https:\/\/doi.org\/10.1186\/s12885-015-1498-0.","journal-title":"BMC Cancer"},{"issue":"1","key":"1459_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/cncr.30968","volume":"124","author":"HS Tran Cao","year":"2018","unstructured":"Tran Cao HS, Zhang Q, Sada YH, Chai C, Curley SA, Massarweh NN. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Cancer. 2018;124(1):74\u201383. https:\/\/doi.org\/10.1002\/cncr.30968.","journal-title":"Cancer"},{"key":"1459_CR48","doi-asserted-by":"publisher","first-page":"1532835","DOI":"10.1155\/2017\/1532835","volume":"2017","author":"CSM Lau","year":"2017","unstructured":"Lau CSM, Zywot A, Mahendraraj K, Chamberlain RS. Gallbladder carcinoma in the United States: a population based clinical outcomes study involving 22,343 patients from the surveillance, epidemiology, and end result database (1973-2013). HPB Surg. 2017;2017:1532835. https:\/\/doi.org\/10.1155\/2017\/1532835.","journal-title":"HPB Surg"},{"key":"1459_CR49","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.2147\/OTT.S131873","volume":"10","author":"KM Leng","year":"2017","unstructured":"Leng KM, Liu YP, Wang ZD, Zhong XY, Liao GQ, Kang PC, et al. Results of adjuvant radiation therapy for locoregional perihilar cholangiocarcinoma after curative intent resection. Onco Targets Ther. 2017;10:2257\u201366. https:\/\/doi.org\/10.2147\/OTT.S131873.","journal-title":"Onco Targets Ther"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-1459-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-020-1459-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-020-1459-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:27:24Z","timestamp":1610584044000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-020-1459-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,15]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1186\/s13014-020-1459-x","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,15]]},"assertion":[{"value":"30 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}